Velpas S Tablet

Velpas S tablet contains sofosbuvir and velpatasvir as active components. It is indicated for the treatment of chronic hepatitis C, a liver infection caused by the hepatitis C virus (HCV). Treatment duration with this combination is often shorter than earlier regimens. The duration may vary based on factors including HCV genotype, prior treatment exposure, and presence of liver cirrhosis. Successful treatment with Velpas S tablet can substantially reduce liver inflammation and fibrosis secondary to HCV infection. Achievement of viral eradication can significantly lower the risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma (a type of liver cancer).

Velpas S tablet should not be used in patients with known allergy or hypersensitivity to sofosbuvir, velpatasvir, or any component of the formulation. Safety and efficacy of the sofosbuvir and velpatasvir combination have not been established in children under 18 years of age. Use in the paediatric population is currently limited. Alternative treatment options or dosage adjustment may be considered in these cases.

To treat chronic hepatitis C (HCV) infection.

Sofosbuvir is a direct-acting antiviral drug (DAA) that inhibits the replication of the HCV virus by targeting a specific protein necessary for viral replication. Velpatasvir is also a DAA that works by blocking the action of another protein involved in the HCV replication process.

Read the instructions carefully before taking Velpas S tablet. Take them as directed by your doctor. Take it with or without food. This will help to improve absorption. If you experience side effects, stop taking them and talk to your doctor.

Velpas S tablet cause some side effects like all medications, although not everyone will experience them. Serious: Hepatitis B reactivation Severe allergic reactions Common: Headache Fatigue Nausea Insomnia Diarrhea Itching (pruritus) Decreased appetite Muscle or joint pain Rash Dizziness

Before initiating treatment, individuals should be screened for hepatitis B virus (HBV) infection due to the risk of HBV reactivation. Close monitoring of liver function and HBV DNA levels is necessary during and after treatment, particularly for those with a current or prior HBV infection. Additionally, potential drug interactions with other medications should be carefully evaluated, and healthcare providers should be informed about all current medications. Individuals taking amiodarone should be closely monitored for severe bradycardia (decreased heart rate) when co-administered with this medication. Dose adjustments are necessary for patients with severe renal impairment or end-stage renal disease. Assessing the potential impact on psychiatric health, especially in individuals with a history of psychiatric disorders, is necessary. Pregnancy and breastfeeding considerations should be discussed with a healthcare provider, and caution is advised for specific populations such as those with HIV/HCV co-infection and liver transplant recipients.